Medical Devices

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

Investors sue medical device maker Integer Holdings, alleging misleading statements led to a catastrophic 32% stock drop. What went wrong behind the scenes?

With its largest fund yet, the firm is doubling down on breakthrough biotech and medtech, signaling strong investor faith in deep science innovation.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

At MD&M West 2026, Boyd showcases how materials science and regulatory expertise are the unsung heroes behind the next wave of medical wearables.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

As CFO Scott Ullem preps for a key presentation, Edwards balances record innovation and strong financials against new regulatory hurdles. What's at stake?

Amid strategic uncertainty after a rejected takeover, STAAR Surgical appoints two veteran executives as interim co-CEOs while launching a global search.

India’s Polymatech signals a major U.S. market offensive, appointing a seasoned leader to drive growth and explore domestic manufacturing possibilities.

The medical tech firm has confirmed it's evaluating strategic options, including a non-binding offer from Steel Partners to acquire a 51% controlling stake.

VASVIK's 51st awards celebrate India's top scientists, blending service, global recognition, and cutting-edge industrial research for national growth.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

A lawsuit seeks to block drastic cuts to Florida's ADAP program, which could strip thousands of life-saving HIV medication and insurance by March 1.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

Incyte's Zynyz gets a key EU panel's nod, offering a breakthrough for advanced anal canal cancer patients after decades of limited treatment options.

Nuwellis appoints Carisa Schultz as CFO, a strategic move to leverage her public company expertise as it navigates growth and financial challenges.

A new dual-action tablet shows major promise for prostate cancer patients with BRCA mutations, poised to change the standard of care in Europe.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.